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Pro-inflammatory cytokinesa b s t r a c t
In October 2013, the International Life Sciences Institute - Health and Environmental Sciences Institute
Immunotoxicology Technical Committee (ILSI-HESI ITC) held a one-day workshop entitled, ‘‘Workshop
on Cytokine Release: State-of-the-Science, Current Challenges and Future Directions”. The workshop
brought together scientists from pharmaceutical, academic, health authority, and contract research
organizations to discuss novel approaches and current challenges for the use of in vitro cytokine release
assays (CRAs) for the identification of cytokine release syndrome (CRS) potential of novel monoclonal
antibody (mAb) therapeutics. Topics presented encompassed a regulatory perspective on cytokine release
and assessment, case studies regarding the translatability of preclinical cytokine data to the clinic, and
the latest state of the science of CRAs, including comparisons between mAb therapeutics within one plat-
form and across several assay platforms, a novel physiological assay platform, and assay optimization
approaches such as determination of FcR expression profiles and use of statistical tests. The data and
approaches presented confirmed that multiple CRA platforms are in use for identification of CRS potential
and that the choice of a particular CRA platform is highly dependent on the availability of resources for
individual laboratories (e.g. positive and negative controls, number of human blood donors), the assay
through-put required, and the mechanism-of-action of the therapeutic candidate to be tested.
Workshop participants agreed that more data on the predictive performance of CRA platforms is needed,
and current efforts to compare in vitro assay results with clinical cytokine assessments were discussed. In
summary, many laboratories continue to focus research efforts on the improvement of the translatability
of current CRA platforms as well explore novel approaches which may lead to more accurate, and
potentially patient-specific, CRS prediction in the future.
 2016 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
As a result of the CD28 superagonist TGN 1412monoclonal anti-
body (mAb) cytokine storm incident in 2006, cytokine release assays
(CRAs) have become more commonly used as hazard identification
and risk assessment tools for therapeutic candidates, particularly
mAbswith thepotential to elicit adversepro-inflammatory cytokine
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(CRS) is a relatively rare event in the clinic, evaluating the potential
of certain novel therapeutic mAbs to cause CRS is now part of pre-
clinical safety testing [4]. Severe CRS is reported to have occurred
in approximately 50% of recipients administered muromonab-CD3
(OKT3, an anti-CD3mAb), before the introduction of high-dose cor-
ticosteroid pre-treatment [5], although in subsequent protocols
using a lower dose, pretreatment with anti-inflammatory agents
and a slower infusion rate also reduced the risk. Moderate-to-
severe CRS is reported in a small number of multiple sclerosis
patients given alemtuzumab (Campath-1H), an anti-CD52 mAb
[6]. Other therapeutic mAbs currently in use such as the tumor
necrosis factor a (TNFa) antagonists infliximab, adalimumab and
certolizumabpegol (Remicade, Humira andCimzia respectively)
and many others such as bevacizumab (Avastin) and natalizumab
(Tysabri) are not associated with CRS [4,7]. Thus, in terms of pre-
dicting the safety of novel therapeuticmAbs inman, the CRA should
ideally differentiate between mAbs with moderate-to-severe
clinical risk (e.g. infliximab < alemtuzumab < muromonab-CD3
(Orthoclone OKT3) < TGN 1412).
Significant progress has been made in designing and developing
improved methods for CRAs as a result of the CD28 superagonist
TGN 1412 incident. In 2007, a solid-phase CRA, which involves
the co-incubation of human peripheral blood mononuclear cells
(PBMCs) with mAbs that have been dry-coated onto a tissue cul-
ture plate, was shown to be predictive for the cytokine release
potential of TGN 1412 [8]. In 2009, the European Medicines Agency
(EMA) held a workshop to discuss in vitro CRAs, with the conclu-
sion that while a specific assay could not be endorsed at that time,
CRAs have a place in predicting the effect of a product in humans
[9]. Currently, a number of in vitro assay formats can be considered
when evaluating the potential for cytokine release for hazard iden-
tification by a novel therapeutic. Various CRA platforms have been
designed to identify mAbs that can be associated with CRS, how-
ever, not all CRA platforms can discriminate between mAbs induc-
ing mild or moderate cytokine release, nor can they be used to
determine a threshold where the levels of cytokines released
may be associated with serious adverse events in humans. The
diversity in the modes of action of specific drugs in the induction
of cytokine release may require the availability of adapted or
flexible CRA platforms to identify potential hazard in the clinic
for a particular therapeutic candidate. As pharmaceutical
companies become more familiar with the mechanisms related
to mAb-induced cytokine release, new assays, platforms and data
interpretation approaches are being adopted.
Considerable progress has been made in understanding mecha-
nistic aspects of CRS as well as in developing CRA formats suitable
for hazard identification. Thus, the International Life Sciences
Institute - Health and Environmental Sciences Institute Immuno-
toxicology Technical Committee (ILSI-HESI ITC) Cytokine Release
Assay Working Group set out to address the scientific issues per-
taining to CRA conduct and CRS risk assessment in a multi-
pronged approach. First, in 2013, ILSI-HESI ITC sponsored a survey
of pharmaceutical companies, contract research organizations, and
academic laboratories that demonstrated that a variety of in vitro
assay approaches were used, including testing strategies, assay for-
mats and reporting and interpretation of CRA data which was sub-
sequently published [2]. The survey indicated that variations in
assay design include solution and/or solid phase based assays,
the use of either various dilutions of whole blood (WB), PBMCs,
or peripheral blood leukocytes (PBLs) as responder cells, and in
some cases, the capture of mAbs on plates or beads via Fc using
protein A or antibodies to Fc. The survey also indicated that posi-
tive CRA controls vary across laboratories with many using anti-
CD3 reagents, while others use anti-CD28 superagonist mAbs (such
as TGN 1412 homologs) or LPS. Some laboratories also includeother marketed mAbs as positive controls. Negative controls
include phosphate buffered saline, tissue culture medium, isotype
mAb controls or marketed mAbs not known to cause clinical cyto-
kine release. Data readouts vary across laboratories from concen-
tration of cytokines (e.g. pg/mL), ratios relative to negative
controls and/or rank order comparison to other mAbs tested. Over-
all the results from the survey highlighted that there are no stan-
dard approaches, and the alignment of technical procedures for
frequently used formats may pave the way for a more harmonized
assay system.
Next, on October 22, 2013, in Silver Spring, Maryland, the ILSI-
HESI ITC Cytokine Release Assay working group sponsored a 1-day
workshop entitled, ‘‘Workshop on Cytokine Release: State-of-the-
Science, Current Challenges and Future Directions”. This workshop
brought together 93 experts in the field from pharmaceutical, aca-
demic, health authority, and contract research organizations to dis-
cuss novel technologies, experimental designs, practices and
scientific challenges. The workshop included both oral and poster
presentations of the latest science concerning CRA design, use,
and interpretation, and concluded with an open panel discussion
featuring the speakers. Topics presented encompassed a regulatory
perspective on cytokine release and assessment, 2 case studies
regarding the translatability of preclinical cytokine data to the
clinic, and the latest state of the science of CRAs, including compar-
isons between mAb therapeutics within one platform and across
several assay platforms, a novel physiological assay platform, and
assay optimization approaches such as determinationof FcR expres-
sion profiles and use of statistical tests. This manuscript summa-
rizes the scientific presentations and provides a current view on
the approaches being adopted to identify the risk of CRS for novel
therapeutic candidates.2. Cytokine release and assessment: a regulatory perspective
Following the TGN 1412 incident, testing for cytokine release-
inducing activity has been increasingly included in the nonclinical
studies conducted to support clinical testing of mAbs [1]. Results of
in vitro cytokine release testing are now frequently included in
regulatory submissions when the therapeutic target is character-
ized as being involved in immune activation. Further, CRA results
are also often submitted for mAbs with targets that have not been
pharmacologically characterized as immune activators but are
expressed on immune cells, or for products such as immune check-
point inhibitors that are designed to disrupt immune inhibitory
signals [2]. During the workshop, both Whitney Helms from the
US Food and Drug Administration and Gabriele Reichmann from
the Paul Ehrlich Institute described cytokine release and assess-
ment from a regulatory perspective.
The conclusions from the EMA 2009 cytokine release workshop
(that cytokine release assays have a place in predicting the poten-
tial of a product to trigger cytokine release in humans [9]) suggest
that assays should be customized taking into account the degree of
knowledge of the mechanism of action of the product. Data derived
from these assays should be considered for hazard identification
purposes rather than for accurate and reliable risk quantification
purposes. Further regulatory guidance on cytokine release testing
has not been developed in the EU and there are still open questions
regarding the products for which investigators should perform
cytokine release testing and which assay format(s) they should
use. Similarly, the United States Food and Drug Administration
(FDA) does not currently have a requirement for any particular
assay that must be used for the assessment of cytokine release.
When FDA has requested cytokine assessments, sponsors have
commonly been referred to Stebbings et al. and Römer et al. for
information on the design of in vitro testing methods [8,10].
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and the recommendations for the methodological requirements for
doing so, the regulatory experience with cytokine release testing at
Paul-Ehrlich-Institute was reviewed based on clinical trial applica-
tions for first-in-human studies with mAbs and related products.
Based on this review, in vitro cytokine assessment would be rec-
ommended for mAbs targeting cellular receptors, especially if
expressed on immune cells. In addition, the mode of action of
the individual product should be taken into account to estimate
its cytokine-inducing risk. An antagonistic mAb would be associ-
ated with a lower risk, while a higher cytokine-inducing risk would
be attributed to a mAb with cytotoxic effector function, or a mAb
which is agonistic or immunostimulatory. For this latter group of
products, knowledge of the mechanism of action should prevail
with regard to risk assessment in the case of negative in vitro cyto-
kine release data. In addition, in vitro cytokine release data might
be recommended when manufacturing changes are made to a clin-
ical candidate with known or mechanistic potential for cytokine
release or when two products for which there is limited clinical
experience are proposed for use in combination, even if the indi-
vidual mAbs have not demonstrated cytokine release potential.
When considering the format of the in vitro CRA, a definitive
recommendation would not be made as it needs to be relevant to
the understanding of mechanism of action of the product being
tested. Assays using WB or PBMCs would be acceptable; while
WB assays are considered more physiological, PBMC assays may
be more sensitive to reveal a cytokine signal. Depending on the
mechanism of action (e.g. products targeting CD3 or T-cell costim-
ulatory ligands), other assay formats can be more appropriate.
Regarding the presentation of the mAb, a soluble assay format
would be sufficient in the event of positive signal in the CRA.
Otherwise, some form of cross-linking of the mAb would be recom-
mended. The cytokines to be measured are dependent on the target
and anticipated mechanism of action of the therapeutic mAb. For
example, from data submitted to the Paul-Ehrlich-Institute, it is
known that several mAbs associated with cytokine release
in vivo induce the expression of IL-6, IL-8, and/or TNF-a in CRAs
in vitro.
One of the most difficult issues is the interpretation of CRA
results. Currently, FDA and EMA have not required that CRA be
conducted under Good Laboratory Practice regulations, in part
because no standard or generally-accepted assays are available.
Assay outcomes show high inter-donor variability in responses,
making the inclusion of an adequate number of donor samples
an important factor in the interpretation of the assay, however, a
definitive recommendation on the number of donors to be tested
is not possible as this would vary with assay read-outs and perfor-
mance. Also, the absolute levels of the produced cytokines vary
depending on the platform used, and it is often difficult to say what
constitutes a true positive result. For this reason, one critical aspect
of the study design is the inclusion of positive and negative con-
trols. While LPS or PHA are sometimes used as positive control
reagents, the inclusion of control mAbs that are known to induce
cytokine-release is generally considered more appropriate. Selec-
tion of the control mAb could depend on the mechanism of action
of the product to be evaluated, e.g. muromonab-CD3 or TGN 1412
for T cell targeting products; alemtuzumab and/or rituximab for
products with cytotoxic effector function. Data interpretation can
also be enhanced by the inclusion of control mAbs that have been
shown clinically not to result in cytokine induction, or that have
some potential to induce cytokines, but not to a level that has
resulted in clinically adverse events.
Despite the challenges associated with interpretation of CRA
data, cytokine release assessment has become an increasingly uti-
lized tool used for the prediction of product safety, particularly for
biologic products. The finding of positive results in a CRA raises thepossibility that the determination of the starting dose and dosing
regimen need to take CRS potential into consideration. The devel-
opment of a well-established assay or assays that can be used to
reliably predict the potential of a product to initiate cytokine
release syndrome, therefore, remains an area of ongoing interest
from a regulatory perspective.
2.1. Translatability of preclinical cytokine data
Interpretation of CRA data may be challenging for reasons that
include the inability to discriminate between a mild and moderate
response in patients, or to determine a threshold of cytokine pro-
duction in vitro that will translate to a severe adverse event in
humans. Despite these challenges, cytokines are included in non-
clinical and clinical studies as safety biomarkers. Although the
translatability of the nonclinical cytokine data is not absolute, in
some cases they are predictive of risk in human populations.
2.1.1. Case study #1: Using in vitro cytokine data to determine the
first-in-human dose
One example presented by Patricia Ryan (MedImmune)
involved MEDI-565 (AMG 211), which is a novel bispecific single-
chain antibody of the BiTE (bispecific T cell engager) class that
transiently links carcinoembryonic antigen (CEA) on cancer cells
with CD3 on T cells. Binding of MEDI-565 to CEA and CD3 results
in T-cell-mediated killing of cancer cells expressing CEA; MEDI-
565 is being developed as a treatment for CEA-expressing cancers.
Concomitant binding of MEDI-565 to CEA and CD3 results in acti-
vation and proliferation of T cells and release of pro-inflammatory
cytokines. Based on this mechanism of action, the ability of MEDI-
565 to induce proliferation of T cells and production of cytokines in
an in vitro PBMC assay system was investigated as part of the non-
clinical safety assessment. In vitro, the MEDI-565 concentration
response relationship for T-cell activation, redirected cancer cell
lysis, and concomitant cytokine release was analyzed using PBMCs
from healthy human donors. Activation of T cells, cancer cell lysis,
and concomitant cytokine release by MEDI-565 exclusively
occurred in the presence of cancer cells expressing CEA. Results
from these in vitro studies on human PBMCs demonstrated that
the ability of MEDI-565 to induce cytokine release and prolifera-
tion of T cells required engagement of both CD3 on T cells and
CEA on target cells. These in vitro cytokine release results were
used as part of a strategy to determine a minimal anticipated bio-
logical effect level (MABEL) and to select a reasonable maximal safe
starting dose for MEDI-565.
2.1.2. Case study #2: Translatability of pre-clinical cytokine data to
clinical studies
In another case study presented by Marie-Soleil Piche (Charles
River Laboratories), cytokine data obtained in rats and monkeys
partially translated to findings in humans. This case study was
divided into 3 sections: (1) initial nonclinical studies in rats and
monkeys; (2) follow up nonclinical studies in rats and monkeys
with a modified compound; (3) initial clinical study with the mod-
ified compound. The test article was designed to treat patients
with advanced solid tumors by targeting two distinct pathways
of tumor progression involving cell proliferation and angiogenesis.
Several toxicity findings in the mid- and high-dose groups were
noted in the initial rat and monkey studies, including mortality,
reduced activity, changes in the liver, kidney, adrenals, spleen,
lymph node, and bone marrow, reduced food consumption,
increased white blood cell counts and altered coagulation. Serum
TNF-a levels were higher compared to historical data in several
animals from different dose groups in both species, however, in
the rat nonclinical study, most animals from the control group also
had higher levels of TNF-a. Therefore, given the inter-animal
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ered to be related to test article administration. Increases in serum
IL-6 concentrations were observed in both the rat and monkey
studies, while increases in serum IFN-c were only observed in rats.
Evidence of complement activation following dosing was also
noted in the monkey study: C3a and Bb levels were higher follow-
ing dosing while total Hemolytic Complement activity (CH50)
levels were generally decreased. In both species, partial reversibil-
ity was observed for some findings following the recovery period.
Based on the observations from both nonclinical studies, the 1st
generation test article was modified to reduce its toxicity, and
the modified test article (2nd generation product) was evaluated
in a subsequent rat and monkey nonclinical studies.
In the follow up rat and the monkey studies, using the modified
test article, microscopic changes in the liver, kidney, spleen and BM
were still observed but the clinical signs were generally less severe
than those observed with the original test article. Increases in C3a
and Bb fragments were still observed in monkeys following dosing.
Serum cytokine levels of IL1-b, TNF-a, and IFN-c were below or
close to the lower limits of quantitation (LLOQ) in both species,
while IL-6 remained high following dosing in monkeys. Therefore,
the rat seemed less sensitive than the monkey to the modified test
article. Release of cytokine and inflammation markers, such as c-
reactive protein, generally occur at lower levels in rats than in
monkeys [11]. Overall, these data suggested that the 2nd genera-
tion product was less toxic than the original test article, and the
2nd generation product was brought forward for testing in a Phase
I clinical trial.
Patients received 4 cycles of treatment. Each cycle was com-
prised of 2 doses of the product administered 2 weeks apart. If
there were no dose limiting toxicities during the first cycle, the
study could proceed with dose escalation to the next cohort. Blood
samples for cytokine analysis were taken at pre-dose as well as at
2, 6, and 24 h post-dose following the first 2 cycles of treatment,
corresponding to four doses of product. Serum levels of IL-1b, IL-
1RA, IL-12, IP-10, IFN-a, IFN-c and G-CSF were analyzed. For most
patients, circulating levels of IL-1b, IL-12, IFN-a and IFN-c were
below the LLOQ, however, IL6 and IL-1RA levels were higher 6 h
following dosing, which was consistent with the circulating IL-6
elevations observed in the monkey. Therefore, in this case study,
a certain degree of similarity existed between the cytokine data
generated in nonclinical (rats and monkeys) and clinical studies.
In general, monkeys were more predictive of a potential cytokine
release than rats. Indeed, IFN-c and IL-1b were below the LLOQ
in both the clinical and the monkey studies while IL-6 level was
increased in both the clinical and the monkey studies.
2.2. State of the science
2.2.1. Comparison of cytokine release across mAb therapeutics
Despite wide-spread use of solid-phase CRAs in the evaluation
of certain therapeutic mAbs, little comparative data exists thatTable 1
Summary of detection cytokine release secretion across 3 different CRA assay platforms w
Assay Platforma mAb tested
Strong CRS association:
OKT3, alemtuzumab, CD28 superagonist
Solid phase Cytokines detectedb
High density PBMC Pre-culture Cytokines detected
PBL-HUVEC co-culture Cytokines detected
a See main text for description of the assay platforms.
b Cytokines (IFN-c, IL-1b, IL-2, IL-4, IL-6, IL-8, IL-10, TNF-a, IL-12p70) were measured u
Magnetic Bead Panel, EMDmillipore Corp.) Detection of concentration-dependentP 3-f
from 3 or more donors was deemed to be a positive cytokine response.
c Not determined.evaluates the value of this approach for predicting CRS. During
the workshop, Richard Stebbings presented the work carried out
at the National Institute for Biological Standards and Controls
(NIBSC) towards the comparison of cytokine release across multi-
ple mAb therapeutics.
TGN 1412 was compared to muromonab-CD3, alemtuzumab
and 9 other mAbs using a wet-coat solid-phase CRA that utilizes
non-tissue culture treated 96 well polypropylene microtitre plates
to achieve high binding density as an alternative to air drying [5].
Culture supernatants from human peripheral blood mononuclear
cells added to these tissue culture plates were assayed for cytokine
release after 24–72 h. Only TGN 1412 and muromonab-CD3 stim-
ulated T-cell mediated cytokine release characterized by signifi-
cant (p < 0.0001) release of IL-2 and 9 other cytokines. Compared
to muromonab-CD3, TGN 1412 stimulated only IL-2 release to a
significantly greater extent (p < 0.0001). The ability of TGN 1412
to stimulate 27.46-fold more IL-2 release than muromonab-CD3
correlated with its ability to stimulate 24.67 times more CD4+ T-
cells producing this cytokine, implying a greater level of T cell acti-
vation. However, TGN 1412 appears not to stimulate more T cells
than muronomab-CD3 since other cytokine release is comparable,
but rather it overrides CD4+ T helper cell cytokine memory (e.g.
Th0, Th1, Th2, Th17, Th22 polarization) to cause a wide range of
subsets to co-release IL-2 that otherwise would not, likely due to
the ability of CD28 to promote IL-2 mRNA stability [8]. This differ-
ence implies that massive IL-2 release was responsible for the
severity of the CRS associated with TGN 1412, compared to
muromonab-CD3. No significant IL-2 release was observed with
alemtuzumab, but significant (p = 0.0177) non-T cell mediated
TNF-a release was observed. These results demonstrate that the
PBMC solid-phase cytokine release assay is able to predict T-cell
mediated cytokine release associated with the use of therapeutic
mAbs. A complicated picture is emerging in which multiple mech-
anisms of cytokine release involving different subsets of immune
cells are involved in CRS.
2.2.2. Comparison of cytokine release across platforms
As assay systems differ across laboratories, a comparison of
three platforms was carried out that directly compared the
responses to mAbs with a strong association with CRS (e.g. alem-
tuzumab, OKT3, CD28 superagonist), mAbs with weak or rare asso-
ciation with CRS (rituximab, trastuzumab), and a mAb with no
established association with CRS (infliximab). Madeline Fort pre-
sented work carried out at Amgen to help address this question.
The platforms chosen included a solid phase CRA with dry coating
of mAb to wells [8,12], a solution phase CRA with high density
PBMC pre-culture [10], and a co-culture CRA of peripheral blood
leukocytes (PBL) with endothelial cells [7,12] (Table 1).
For all of the CRA platforms, cytokines were assessed using a
multiplex array Luminex system which included detection of
the following: IFN-c, IL-1b, IL-2, IL-4, IL-6, IL-8, IL-10, TNF-a, IL-
12p70 (Milliplex MAP Human Cytokine/Chemokine Magnetic Beadith mAbs with varying CRS potency in vivo.
Weak or rare CRS association:
rituximab; trastuzumab
No CRS association: infliximab
Cytokines detected Cytokines detected
No cytokines detectedb NDc
No cytokines detected No cytokines detected
sing a multiple array Luminex system (Milliplex MAP Human Cytokine/Chemokine
old increases above negative controls of more than 1 cytokine using PBMCs or PBL
C. Grimaldi et al. / Cytokine 85 (2016) 101–108 105Panel). As summarized in Table 1, in the solid phase CRA, alem-
tuzumab, muromonab-CD3, and rituximab produced pro-
inflammatory cytokines as has been described in the literature
[12]; however, mAbs with weak or no established association with
CRS in patients (infliximab and trastuzumab) as well as an anti-
streptavidin human IgG2 non-specific control mAb also produced
pro-inflammatory cytokines, including TNF-a, IL-6, IL-8, and IL-
1b, at levels equivalent to muromonab-CD3 and rituximab with
PBL from several donors, suggesting the possibility of false posi-
tives with this platform. High density pre-culture of PBMCs
resulted in the detection of pro-inflammatory cytokines by soluble
CD28 superagonist mAb in agreement with published results [10].
Co-culture of PBL with human umbilical vein endothelial cells
(HUVEC) provided sufficient detection of T cell-associated cytoki-
nes such as IL-2, IL-4, IL-10, IFN-c, TNF-a, IL-6, and IL-8 from
OKT3 and a CD28 superagonist mAb. In this platform, alem-
tuzumab induced IFN-c, TNF-a, IL-6, and IL-8 but not IL-2, which
suggests that innate immune cells, such as natural killer cells, are
the predominant targets over T cells for alemtuzumab. The PBL/
endothelial co-culture assay did not detect cytokine release in
response to mAb with weak, rare, or no association with CRS
in vivo, including infliximab, trastuzumab, and rituximab. There-
fore, the PBL/endothelial cell co-culture CRA provided the best cor-
relation for the clinical outcome of strong CRS potential for the
therapeutic mAbs assessed that target immune-related cell surface
receptors.
2.2.3. Physiological conditions may provide more in vivo relevance in
newly developed assays
As some groups have made significant progress towards provid-
ing an optimal assay format to test biologics, one important, and
ongoing, consideration is the extent to which assays reflect the
physiological environment. To achieve a more physiological envi-
ronment, endothelial cells and PBMCs are co-cultured and used
for CRA testing [8,12]. Some literature reports suggest that
endothelial cell/PBMC co-culture is favorable, as this kind of assay
reflects the cell interactions in vessels where cytokine release and
vascular leak occur [7,12]. Because mature endothelial cells in the
body are found lining blood vessels, they cannot be obtained read-
ily from healthy volunteers. Endothelial cells are therefore rou-
tinely grown from umbilical veins, which are used as the
interface with PBMCs for cytokine release testing. This means that
co-culture assays are comprised of heterologous mixtures of cells.
Investigators at the National Heart and Lung Institute, Imperial
College London, have generated the hypothesis, described during
the workshop by Daniel Reed and Jane Mitchell, that this could
result in a tissue mismatch that occurs when cells from one donor
are mixed with those of another [13], and that this might be
responsible for some of the limitations of HUVEC/PBMC co-
culture assays. In line with this, others have also suggested that
the use of heterologous co-culture assays is a potential limitation
in endothelial cell/PBMC co-culture assays used to test for CRS
responses [2]. Recently the investigators from Imperial College pre-
sented an assay that employs endothelial cells derived from adult
progenitors, so-called blood outgrowth endothelial cells (BOEC)
together with PBMCs from the same donor [14]. Importantly, this
autologous BOEC/PBMC co-culture assay was found to respond to
anti-CD28 superagonist mAb to release cytokines associated with
CRS in a way that delineated responses from less severe cytokine
storm causing mAbs such as alemtuzumab and non-cytokine storm
causing mAb such as bevacizumab. Working together with
Professor Richard Stebbings and the National Institute for Biologi-
cal Standards and Control, the Imperial College team also recently
demonstrated that this assay is superior to heterologous donor
assays (HUVEC/PBMC co-cultures) [14]. The authors concluded
that the improved ‘signal to noise’ response seen in theirautologous BOEC/PBMC co-culture assay was a result of the
removal of the confounding factor of tissue mismatch. Further-
more, unlike HUVEC/PBMC co-culture assays, BOEC/PBMC co-
cultures contain matched donor cells and can be used to study
cytokine storm reactions in target patient groups. This is impor-
tant, since recent work has shown that BOECs derived from
patients with the lung conditions pulmonary hypertension [15]
or chronic obstructive pulmonary disease [16] retain a disease phe-
notype in laboratory assays. In this way, BOEC/PBMC assays repre-
sent an optimal system for a personalized medicine approach and
could be used to construct highly translatable co-culture assays.
The challenge now will be to determine how to scale up these
assays in order to produce an off-the-shelf prototype for broad
use by the pharmaceutical industry.
2.2.4. Optimizing assay conditions for detection of cytokine release
potential
Although significant progress in the use of bioassays to predict
CRS has been made, to date no consensus exists on the optimal
assay format that should be used when screening uncharacterized
mAb therapeutics. Traditionally, the soluble phase CRA format
(mAbs free in culture media with PBMCs) and the solid phase
CRA format (mAbs immobilized to culture plate) have been utilized
to assess responses mediated by either the Fc or Fab’ portion of
mAbs. However, following the difficulties in sensitively replicating
the cytokine storm induced by TGN 1412, this may be an
over-simplified approach which may not be appropriate for all
mAbs.
Through the NC3Rs (National Center for 3 Rs) UK government-
funded collaboration (CRACK-IT) the University of Southampton
and Envigo CRS Ltd (‘‘Envigo”, formerly known as Huntingdon Life
Sciences), represented at the meeting by Daniel Gliddon, is
attempting to develop reliable and sensitive assays for the predic-
tion of CRS. The approach comprises the evaluation of a range of
assay formats suitable for measuring cytokine induction mediated
by target or effector cells in response to leukocyte-expressed,
tissue-expressed or soluble target antigens. The primary aim of
the project is to develop an assay that can be applied to effectively
predict the clinical outcome for a candidate mAb based on the
individual characteristics of that mAb and to support this, a range
of culture conditions and specific assessments are being investi-
gated. These include the sensitive measurement of cytokine
release, assessment of cellular proliferation, analysis of Fc gamma
receptor (FccR) genotypes, assessing the proportions of key
immune cell populations in donor samples and appropriate power-
ing to enable statistical analysis. Work is currently focusing on the
optimization of assay conditions using PBMC samples obtained
from healthy donors by incubation with a range of mAbs known
to be associated with CRS or control mAbs, and assessing for cyto-
kine production and cell proliferation. Additionally, information on
the FcR expression at both the cellular and genetic level for each
donor is analyzed to determine their relationship to responses in
the assay.
Results to date indicate that culture conditions supportive of
reliable and sensitive assay formats for testing induction of cytoki-
nes associated with CRS may have been identified. Further, the pat-
tern of cytokine production observed in the assays is specific to
those cytokines associated with CRS clinically, including those
cytokines induced by TGN 1412. Work is ongoing to optimize assay
parameters and to fully analyze the impact of FccR expression on
cytokine release. In investigating the mechanism of enhancement
of PBMC responsiveness to TGN 1412 precultured at high density,
the University of Southampton have recently shown monocyte
upregulation of FcgRIIb as the prerequisite factor [17], rather than
increased T cell sensitivity or B cell expression of FcgRIIb as
described by others [10,18]. If successful, Envigo intends to
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nonclinical safety evaluation of novel mAb therapeutics.
2.2.5. Statistical analysis can provide guidance for optimized assay
conditions
In providing insight towards optimizing assay conditions, Mindi
Walker from Janssen described how statistical analysis can be
applied to assist in experimental design and data analysis [19]. Sta-
tistical analyses were conducted on historical data generated from
a WB assay which analyzed 11 cytokines using mAbs immobilized
on protein A beads. The data set included 32 different test mAbs
using 44 donors over 12 different experimental runs with runs
containing between 3 and 8 unique donors. Review of the data
set revealed that the data were approximately log normal and
therefore, log transformation of the data would allow use of an
Analysis of Variance (ANOVA) using Tukey’s posttest, which is a
more powerful statistical test than the Kruskal-Wallis ANOVA on
ranks that was currently in use. Statistical analyses were con-
ducted to look at sources of assay variation, to identify outliers,
and to optimize powering of the assay. Results from a variance
component analysis model showed that the greatest source of vari-
ation in the assay was inter-donor variation, and therefore assay
power could be increased by increasing the number of donors in
a given run. Additionally, power analysis results showed that run-
ning samples from 16 donors without replicate wells increased the
power to detect smaller differences in cytokine responses between
treatment groups than an assay setup of samples from 8 donors in
triplicate wells. Power analysis should be performed on the CRA
assay of choice to determine the number of donors and replicates
needed to detect differences in a given laboratory. In general,
donor to donor (inter-donor) variation is greater than within donor
(intra-donor) variation and therefore increasing the donor number
within a given run will increase assay power. Plate variation was
also analyzed and results showed some variation, which was
inconsistent across cytokines, in both the WB assay plate and the
Meso Scale Discovery (MSD) cytokine analysis plate. In order to
mitigate any plate effects that occur, plates may be arranged with
samples from a specific donor in each row and treatments random-
ized to different columns for each new experiment. Results from
the outlier analysis showed that visually unusual data points were
within normal inter-donor variation, therefore, better understand-
ing of the sources of variability among blood donors would
increase assay robustness. In addition, the data were analyzed
using 6 predictive modeling algorithms which included linear dis-
criminant analysis (LDA), recursive partitioning (RP), neural net-
works (NN), support vector machines (SVM), random forests (RF),
and naïve Bayes (NB). These models gave a probability of a new
test compound being similar to compounds identified during
model training as having no to mild CRS or moderate to high CRS
potential. The retrospective analysis of the assay data identified
areas for improvement in both the assay conduct and analysis of
the data. The assay now has increased power to detect differences
in treatments, data analysis has been optimized and includes more
powerful statistical tests, individual runs that perform outside con-
trol limits or donor outliers can be identified, and plate effects have
been mitigated. In addition, predictive modeling provided an inde-
pendent and unbiased CRS prediction category which gave added
confidence to the risk assessment for novel compounds. Imple-
mentation of these improvements, along with statistical
approaches, has increased assay robustness and predictability to
increase precision, and thus should increase confidence in CRS
assays by regulatory authorities and clinicians. The analyses pro-
vide an example of statistical tests that should be performed on
this type of data and hopefully inspire others to think about their
assay setup and data analysis in new ways.3. Discussion and future directions
Despite significant progress and groundbreaking research in the
area of bioassays to predict the potential of a mAbs to cause a ‘‘cy-
tokine storm” in humans, many questions remain. The ILSI-HESI
ITC Cytokine Release Assay Working Group survey that was con-
ducted and presented at the workshop by Deborah Finco (Pfizer),
in conjunction with a literature review, highlighted that no con-
sensus exists on the optimal assay format to test the potential of
novel mAbs to cause cytokine storm in patients [2]. Considerable
variation in protocol design and assay format occurs across institu-
tions carrying out such testing. Part of the on-going discussion
regarding CRA platforms is whether there is a need to consolidate
assay design and format, and establish uniform protocols for CRS
testing. The availability of a standard assay platform for CRS pre-
diction would allow the comparison of results for a wide variety
of novel therapeutics by industry and regulatory scientists. How-
ever, there is ongoing debate in regards to which assay format is
optimal for prediction of CRS potential. This debate includes the
ability of an assay to rank order mAbs by perceived degree of
CRS risk in patients, to mimic the pattern of cytokine release
observed in vivo by a particular mAb, to recapitulate physiologi-
cally relevant (‘‘in vivo-like”) conditions, and the number of differ-
ent WB/PBMC donors required for accurate predictive power
[3,10,12,19–22]. Given the difference in mechanisms of action
between different therapeutic mAbs, determination of whether a
‘‘one-size-fits-all” approach is feasible would require enhanced
understanding of technical procedures, practices, and performance,
including positive and negative controls, data interpretation and
clinical use. One outcome from the workshop has been the devel-
opment of ‘‘standard” positive and negative control mAbs for
CRA qualification at the National Institute for Biological Standards
and Controls (NIBSC, Hertfordshire, United Kingdom). Currently,
these controls are being tested in a variety of CRA platforms, and
if the controls demonstrate acceptable performance, these reagents
will be available for use to the wider research community and will
enable better cross-laboratory and cross-platform comparison of
CRA results.
It is conceivable that, because of the unique mechanism of
action of any mAb therapeutic, we will never be in a position to
define an assay that will universally predict risk of cytokine storm.
This raised a question among the workshop participants: are we
correct in focusing so exclusively on assays appropriate for the
mechanism of action of TGN 1412? Furthermore, assay platforms
that are the most appropriate for mAb-mediated cytokine release
may not be ideal for detection of cytokine release induced by other
modalities. For example, Coch and colleagues determined that a
WB assay format was preferable over PBMCs for detection of cyto-
kine release by oligonucleotides which bind to toll-like receptors
[23]. In addition, as described by Patricia Ryan in Case Study #1
above and in the literature, novel immunotherapies for cancer such
as bispecific T cell engagers induce T cell activation and cytokine
production only when target-expressing tumor cells are present
and may require specialized assay formats to allow the sensitive
detection of T cell activation for determination of a minimal
acceptable biological effect level (MABEL) in patients [24,25].
One idea discussed at the workshop to promote confidence in
CRA formats was the establishment of a database comprised of
data from various CRAs and the subsequent results of in vivo cyto-
kine tests in patients receiving therapeutic mAbs. This would
require collecting the serum cytokine data from patients in clinical
trials in a comprehensive and consistent manner in addition to the
in vitro CRA data. Researchers at this conference, however, were
able to present only limited clinical cytokine data due to the fact
that samples are not routinely collected for this assessment in
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able within the organization. Since the workshop, the Nonclinical
Biologics Subcommittee at the Center for Drug Evaluation and
Research of the FDA has initiated a Cytokine Release Data Mining
Project to use both nonclinical and clinical cytokine data to deter-
mine if CRA formats are good predictors of clinical outcomes; the
results from this project will be very informative for the field.
Another option to increase confidence in CRA formats may be to
perform CRAs with toxicology species samples and measure
cytokines in vivo during toxicology studies in that species. Corre-
lates between toxicology species in vitro CRAs and in vivo data
may further support the predictive results obtained with human
cells and translatability to patients. While there is active research
in this area by some groups, the predictive value of the CRA plat-
form for human immune cells may still need to be confirmed with
clinical cytokine data. Clearly, close cooperation and collaboration
among clinical investigators and research laboratories is critical for
confidence in the predictive value of any CRA platform.
It is generally agreed that there is need for a clearer understand-
ing of the underlying immune networks that can allow for the esca-
lation of the immune responses to the detriment of the organism
itself. Pathologic immune response cascades have been observed
with a variety of agents, including bacteria (e.g. sepsis), viruses
(e.g. avian influenza, small pox), and medical interventions such
as graft vs host disease and certain mAb therapeutics (OKT3, TGN
1412, alemtuzumab) [1,5,6]. A systems biology approach to under-
stand the initiating events of immune cell activation that can lead
to development of CRS may be necessary to truly understand all
the possible ‘‘triggers”. This knowledge could then be applied to
the in vitro CRA platforms: permitting the design of a CRA platform
(or platforms) that will capture themost relevant potential immune
signaling cascades for a particular mAb therapeutic target.
Finally, many fields of medicine and biotechnology are increas-
ingly developing personalized approaches whereby drugs or doses
are defined based on an individual patient’s genes and characteris-
tics. Examples include warfarin dose selection based on individual
patient expression of the genes CYP2C9 and VKORC1 [26], and Aba-
cavir hypersensitivity based on HLA⁄B5701 expression [27]. As
most CRA platforms utilize peripheral blood (either whole or iso-
lated cell subsets), it is possible that a screening process could be
designed for individual patients. This may be most relevant when
the health status and/or genetic make-up of a particular patient
may affect the CRS potential of novel therapeutic mAbs. For exam-
ple, if the presence of autoimmune disease results in enhanced
expression of a therapeutic target on immune cells, then use of
healthy donor WB or PBMCs may not be appropriate for under-
standing CRS potential in patients. In such a scenario, testing the
therapeutic in a CRA platform using immune cells from either a
group of donors with autoimmune disease or from prospective
patients enrolled in a clinical trial would be optimal. This approach,
although an intriguing idea, could be very challenging logistically,
especially in clinical trials with large numbers of patients. Growth
in our understanding of the mechanisms underlying CRS in vivo
should result in the development of in vitro CRA platforms that
correlate to in vivo clinical cytokine measurements and greater
confidence in translation of in vitro outcomes to the clinic.
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